C PBTE 01
Alternative Names: C-PBTE-01Latest Information Update: 05 Mar 2024
At a glance
- Originator Curatis
- Class Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Brain oedema
Highest Development Phases
- Phase II Brain oedema
Most Recent Events
- 16 Jan 2024 C PBTE 01 is available for licensing as of 16 Jan 2024. https://curatis.com/partnering/
- 16 Jan 2024 Phase-II clinical trials in Brain oedema (unspecified route) (Curatis pipeline, January 2024)